Vantage Point: Medicare Part D

Share this article:
Over the past decade, numerous changes have impacted the healthcare market and driven marketplace volatility. Among them, managed care continues to influence brand success, and Medicare Part D is creating a new dynamic within the industry.

Additionally, consumers are more educated about the effects and costs of drugs, while physicians are less accessible than ever before, both to the sales rep and patient. Opt-out and opt-in programs allow physicians to eliminate the capture of their prescribing, limiting the manufacturers' ability to understand how best to serve their physician and patient base.

As these changes impact product sales, brand team leaders are charged with combating stagnating product growth. They must turn to evidence-based decision-making to drive efficient and effective brand strategies and tactics. The most effective marketing strategies depend on identifying the population of patients who are potentially eligible for treatment, further enabling marketing efforts to be focused on the unique treatment behaviors, attitudes and degree of influence exhibited by the healthcare stakeholders who play a role in treatment.

Increasingly, pharma companies are integrating anonymized patient-level data (APLD) into business processes to measure brand performance. APLD can be used to develop a patient market map that yields specific data about disease populations and the manner in which they are treated. By populating the map in this way, the brand manager has the benefit of a robust data set that allows for visibility into all aspects of a patient's treatment. In today's times of constrained resources, the map is an invaluable tool.

Heather von Allmen is senior principal, commercial effectiveness, at IMS Health
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Vantage Point

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Vantage Point

Vantage Point: Payers—the "experts" in healthcare research

Vantage Point: Payers—the "experts" in healthcare research

Access to payers is about knowledge, about understanding what they do in their jobs

Vantage Point: Determining "fair market value"

Vantage Point: Determining "fair market value"

Should pharma formulate a super matrix to determine the FMV of research incentives?

Vantage Point: Marketing Support for Clinical Trials

Vantage Point: Marketing Support for Clinical Trials

Pharmaceutical companies must provide robust marketing support for their clinical trials